KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 27 04 2023
accepted: 02 10 2023
revised: 24 09 2023
medline: 20 11 2023
pubmed: 17 10 2023
entrez: 16 10 2023
Statut: ppublish

Résumé

Triple-negative breast cancer (TNBC) is a heterogeneous breast cancer subtype and accounts for approximately 15-20% of breast cancer cases. In this study, we identified KLHL29, which is an understudied member of the Kelch-like gene family, as a crucial tumor suppressor that regulates chemosensitivity in TNBC. KLHL29 expression was significantly downregulated in breast cancer tissues compared with adjacent normal tissues, and low levels of KLHL29 were associated with unfavorable prognoses. Ectopic KLHL29 suppressed, while depleting KLHL29 promoted, the growth, proliferation, migration, and invasion of TNBC. Mechanistically, KLHL29 recruited the CUL3 E3-ligase to the RNA-binding protein DDX3X, leading to the proteasomal degradation of the latter. This downregulation of DDX3X resulted in the destabilization of CCND1 mRNA and the consequent cell cycle arrest at G0/G1 phase. Remarkably, the DDX3X inhibitor RK33 combined with platinum-based chemotherapy can synergistically suppress TNBC that usually expresses low levels of KLHL29 and high levels of DDX3X using cancer cell-derived xenograft and patient-derived organoids models. Altogether, we uncovered the potential role for the KLHL29-DDX3X signaling cascade in the regulation of TNBC progression, thus providing a promising combination strategy for overcoming TNBC chemoresistance.

Identifiants

pubmed: 37845393
doi: 10.1038/s41388-023-02858-5
pii: 10.1038/s41388-023-02858-5
pmc: PMC10656286
doi:

Substances chimiques

DDX3X protein, human EC 3.6.1.-
DEAD-box RNA Helicases EC 3.6.4.13
KLHL29 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3514-3528

Informations de copyright

© 2023. The Author(s).

Références

Cancer Biol Med. 2021 Aug 27;:
pubmed: 34448553
Cancer Cell. 2019 Mar 18;35(3):428-440.e5
pubmed: 30853353
ACS Med Chem Lett. 2010 Dec 31;2(3):252-256
pubmed: 21572541
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Pharmacol Res. 2019 Oct;148:104404
pubmed: 31442578
RNA. 2007 Jan;13(1):116-28
pubmed: 17095540
Cell. 2018 Jan 11;172(1-2):373-386.e10
pubmed: 29224780
Hum Genomics. 2013 May 15;7:13
pubmed: 23676014
Nucleic Acids Res. 2012 Jun;40(11):4998-5011
pubmed: 22323517
BMJ. 2023 May 30;381:e071674
pubmed: 37253507
J Exp Clin Cancer Res. 2020 Oct 29;39(1):229
pubmed: 33121524
Cancer Discov. 2019 Feb;9(2):176-198
pubmed: 30679171
Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188678
pubmed: 35026309
Lancet. 2017 Jun 17;389(10087):2430-2442
pubmed: 27939063
Cancer Res. 2021 Nov 1;81(21):5491-5505
pubmed: 34408002
Acta Pharmacol Sin. 2023 May;44(5):931-939
pubmed: 36266566
Trends Cell Biol. 2000 Jan;10(1):17-24
pubmed: 10603472
Cancer Cell. 2011 Aug 16;20(2):214-28
pubmed: 21840486
Cell Rep. 2022 Mar 1;38(9):110460
pubmed: 35235781
Mol Cell Biol. 1999 Sep;19(9):6276-85
pubmed: 10454574
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Am J Pathol. 2010 Jun;176(6):2607-15
pubmed: 20395447
Autophagy. 2021 Dec;17(12):4323-4340
pubmed: 33977871
Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30566-30576
pubmed: 33203674
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Oncogene. 2008 Jun 26;27(28):3912-22
pubmed: 18264132
Cancer Res. 2018 Aug 15;78(16):4512-4523
pubmed: 29921696
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Clin Transl Med. 2022 Jun;12(6):e848
pubmed: 35696608
Mol Cancer. 2021 Feb 24;20(1):38
pubmed: 33627125
Proc Natl Acad Sci U S A. 2022 Nov 16;119(46):e2207201119
pubmed: 36343244
Mol Cancer. 2015 Nov 05;14:188
pubmed: 26541825
Annu Rev Pathol. 2022 Jan 24;17:181-204
pubmed: 35073169
Trends Biochem Sci. 2017 Nov;42(11):873-886
pubmed: 28947091
Mol Cell. 2022 Jul 21;82(14):2588-2603.e9
pubmed: 35588748
EMBO J. 2004 Apr 21;23(8):1681-7
pubmed: 15071497
EMBO J. 2012 Sep 12;31(18):3745-56
pubmed: 22872150
J Clin Oncol. 2012 May 20;30(15):1879-87
pubmed: 22454417
Cancer Res. 2016 Nov 1;76(21):6340-6350
pubmed: 27634756
Cell Rep. 2019 Jun 18;27(12):3573-3586.e7
pubmed: 31216476
EMBO Mol Med. 2015 Mar 27;7(5):648-69
pubmed: 25820276
Semin Cancer Biol. 2021 Dec;77:29-41
pubmed: 33161141
Nat Commun. 2022 Feb 10;13(1):791
pubmed: 35145111
Nature. 2018 May;557(7706):585-589
pubmed: 29769719
Cancer Treat Rev. 2016 Jul;48:34-41
pubmed: 27343437
Cell. 2004 Oct 29;119(3):381-92
pubmed: 15507209
Pharmacol Res. 2021 Jul;169:105616
pubmed: 33872809
Nat Rev Mol Cell Biol. 2013 Aug;14(8):518-28
pubmed: 23877564

Auteurs

Litong Yao (L)

Department of Breast Surgery, the First Hospital of China Medical University, Shenyang, Liaoning, China.

Qian Hao (Q)

Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.

Mozhi Wang (M)

Department of Breast Surgery, the First Hospital of China Medical University, Shenyang, Liaoning, China.

Yuhai Chen (Y)

Department of Breast Surgery, the First Hospital of China Medical University, Shenyang, Liaoning, China.

Hongyi Cao (H)

Department of Pathology, the First Hospital of China Medical University and College of Basic Medical Sciences, Shenyang, Liaoning, China.

Qiang Zhang (Q)

Department of Breast Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.

Keda Yu (K)

Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.

Yizhou Jiang (Y)

Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.

Zhiming Shao (Z)

Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.

Xiang Zhou (X)

Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China. xiangzhou@fudan.edu.cn.
Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Institutes of Biomedical Sciences, Fudan University, Shanghai, China. xiangzhou@fudan.edu.cn.

Yingying Xu (Y)

Department of Breast Surgery, the First Hospital of China Medical University, Shenyang, Liaoning, China. xuyingying@cmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH